VKTX - Viking Therapeutics, Inc.
NEXT EARNINGS:
Apr 21, 2026
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$103.67
DETAILS
HIGH:
$107.00
LOW:
$99.00
MEDIAN:
$105.00
CONSENSUS:
$103.67
UPSIDE:
207.17%
Market Cap:
3.90B
Volume:
2,247,847
Avg Volume:
2,971,563
52 Week Range:
18.92-43.15
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.77
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
45
IPO Date:
2015-04-28
EPS (TTM):
-3.19
P/E Ratio:
-11.02
Revenue (TTM):
N/A
Total Assets:
715.73M
Total Debt:
137,000
Cash & Equiv:
165.81M
Rev Growth (5Y):
N/A
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-61.5%
Debt/Equity:
0.00
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-11 | $-1.38 | $-0.89 | -55.1% | — | — | — |
| 2025-10-22 | $-0.81 | $-0.70 | -15.7% | — | — | — |
| 2025-07-23 | $-0.58 | $-0.44 | -31.8% | — | — | — |
| 2025-04-23 | $-0.41 | $-0.34 | -20.6% | — | — | — |
| 2025-02-05 | $-0.32 | $-0.28 | -14.3% | — | — | — |
| 2024-10-23 | $-0.22 | $-0.24 | +8.3% | — | — | — |
| 2024-07-24 | $-0.20 | $-0.26 | +23.1% | — | — | — |
| 2024-04-24 | $-0.26 | $-0.27 | +3.7% | — | — | — |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (359.64M) | (109.96M) | (85.89M) | (68.87M) | (54.99M) | (39.49M) | (25.78M) | (22.06M) | (20.58M) | (14.73M) | (23.40M) | (21.88M) |
| EPS | -3.19 | -1.01 | -0.91 | -0.88 | -0.70 | -0.50 | -0.36 | -0.38 | -0.79 | -0.90 | -3.68 | -5.08 |
| Total Assets | 715.73M | 908.32M | 368.49M | 168.53M | 210.66M | 256.50M | 284.26M | 302.31M | 22.12M | 14.54M | 15.44M | 3.04M |
| Total Debt | 137,000 | 1.12M | 1.26M | 1.56M | 29,000 | 359,000 | 662,000 | 0 | 3.45M | 3.27M | 2.15M | 1.57M |
| Cash & Equivalents | 165.81M | 26.68M | 55.52M | 36.63M | 26.37M | 29.12M | 8.38M | 24.78M | 8.99M | 3.08M | 768,550 | 755,857 |
| Operating Cash Flow | (278.69M) | (87.79M) | (73.38M) | (48.40M) | (47.59M) | (21.78M) | (24.75M) | (18.75M) | (14.76M) | (11.07M) | (8.73M) | (1.59M) |
| Free Cash Flow | (278.69M) | (87.79M) | (73.38M) | (48.40M) | (47.59M) | (21.78M) | (24.75M) | (18.75M) | (14.76M) | (11.07M) | (8.73M) | (1.59M) |
| FCF per Share | -2.47 | -0.81 | -0.78 | -0.63 | -0.62 | -0.30 | -0.34 | -0.33 | -0.57 | -0.68 | -1.37 | -0.37 |
| Book Value | 639.06M | 880.28M | 348.42M | 145.32M | 201.88M | 244.34M | 277.12M | 297.75M | 13.46M | 8.04M | 8.72M | (22.13M) |
| Cash & ST Investments | 705.74M | 902.61M | 362.08M | 155.49M | 202.10M | 248.39M | 275.64M | 301.52M | 20.58M | 13.15M | 14.10M | 755,857 |
| ROC Equity | -0.56 | -0.12 | -0.25 | -0.47 | -0.27 | -0.16 | -0.09 | -0.07 | -1.53 | -1.83 | -2.68 | N/A |